Jiangsu Hengrui Medicine Co., Ltd.
A leading Chinese pharmaceutical giant and the top domestic enterprise in anti-tumor drugs, Hengrui holds a leading position in R&D and production. It owns the National Engineering Research Center for Targeted Drugs and a post-doctoral research station, with products covering various targeted drugs and chemotherapy agents, such as Camrelizumab Injection and Fluzoparib Capsules.
Fosun Pharma
Founded in 1994, Fosun Pharma is an international innovation-driven pharmaceutical and health maintenance enterprise rooted in China. In the oncology field, it has built technical platforms for innovative small-molecule drugs, antibody drugs, and cell therapies, focusing on key disease areas such as tumors, immune regulation, metabolism & digestive system, and central nervous system.
BeiGene
A global leading biopharmaceutical company headquartered in Beijing, China. BeiGene has made substantial investments in anti-tumor drug R&D. Its core products, Zanubrutinib andTislelizumab, have seen continuous growth in global sales, with over 100 clinical trials conducted worldwide.
Sun Pharmaceutical Industries Ltd
India's largest pharmaceutical company and the world's fourth-largest generic drug manufacturer, Sun Pharma covers multiple fields including oncology. It excels in producing and selling chronic and acute therapeutic drugs, including APIs, generics, and various anti-tumor medications.
Dr. Reddy's Laboratories Ltd
A major producer of oncology/anti-cancer APIs in India, Dr. Reddy's has an experienced team and supplies key ingredients like kinase inhibitors, androgen receptor inhibitors, and microtubule inhibitors. Its facilities comply with GMP regulations, ensuring anti-cancer drug quality through the QBD (Quality by Design) process.
Takeda Pharmaceutical
A leading Japanese pharmaceutical company, Takeda has deep R&D strength and a rich product portfolio in oncology. It demonstrates remarkable performance in digestion, oncology, cardiovascular & metabolism, hematology, etc., with significant investments in R&D.
Daiichi Sankyo Company, Limited
A renowned Japanese pharmaceutical enterprise, Daiichi Sankyo has unique technologies and products in anti-tumor drug R&D. Its developed ADCs (antibody-drug conjugates) have attracted high attention in the field of cancer treatment.
AstraZeneca (Japanese Branch)
Although a British company, AstraZeneca has a significant R&D and production presence in Japan. It invests heavily in oncology drug R&D, developing a series of targeted drugs and immunotherapies for different tumor types.
Cipla Ltd
A global leader in the pharmaceutical industry and a top player in India, Cipla has optimized a diversified oncology product portfolio, including 32 different targeted formulations. It can complete in-house processes from API production to extensive clinical research.
Lupin Limited
An Indian company renowned for its multi-faceted production capabilities, Lupin's therapeutic areas include oncology. Its oncology production facility in Indore focuses on high-potency drug development, with over 15 manufacturing bases worldwide that meet international regulatory standards.
